NOUR HEART, INC.
Biotech · Private
Nourexal™ (Cyclocreatine Phosphate), a bioenergetic cardioprotective drug that enhances myocardial energy stores during ischemia to extend viable cold storage time of donor hearts for transplantation
- Grants
- $3.6M
- 3 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 10
- 4 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Nourexal™: A Novel Bioenergetic Drug to Increase Donor Heart Utilization | $1,658,923 | |
| Federal grant | Department of Health and Human Services · Phase II · Nourexal™: A Novel Bioenergetic Drug to Increase Donor Heart Utilization | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Nourexal™: A Novel Bioenergetic Drug to Increase Donor Heart Utilization | $1,923,922 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2244 | Cour Pharmaceutical | — | — |
| 2245 | AVEXEGEN THERAPEUTICS INC. | — | — |
| 2246 | CELLF-BIO LLC | — | — |
| 2247 | NOUR HEART, INC. | — | — |
| 2248 | NAPROGENIX, INC. | — | — |
| 2249 | BRIDGENE BIOSCIENCES, INC. | — | — |
| 2250 | OpalGenix, Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- DE NOVO Synthesis of Cyclocreatine and Subsequent Conversion to Cyclocreatine Phosphate Via a Continuous Flow Reactor (CFR) Systemapplication
- Nourin Gene-based Rna Molecular Network: Novel Early Diagnostic And Prognostic Biomarkers For Coronary Artery Disease, Unstable Angina, Stemi/nstemi And Heart Failuregranted
- Novel Bioenergetic/anti Inflammatory Therapyapplication
- Cyclocreatine Phosphate: A Novel Bioenergetic Therapy To Prevent And Treat Ischemia-induced And Aging-related Cardiovascular And Neurodegenerative Diseasesgranted
- A Novel Autophagy-Related Nourin Gene-Based RNA Network as Early Biomarkers for Cardiac Patientsgranted
- Nourin Molecular Biomarkers Diagnose Angina Patients With Negative Troponingranted
- Nourexal: Prevents Ischemic Injury, Rejuvenates Tissues and Protects Against Aging and Aging-Related Diseasesapplication
- Methods Of Organ Protectionapplication
- Phosphagen Synthesisapplication
- Diagnostic Markerapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.